4-hydroxy-tamoxifen
4-hydroxy-tamoxifen - Related Videos
03:12
CreER-LoxP System-Based Target Gene Inactivation: A Tamoxifen-Inducible Cre Recombinase System for Target Gene Knockout in a Mouse Model
0 Views •
2025
This video describes a procedure for target gene knockout using a tamoxifen-inducible Cre-recombinase system following intraperitoneal injection of tamoxifen in a mouse model.
13:41
Monitoring Equilibrium Changes in RNA Structure by 'Peroxidative' and 'Oxidative' Hydroxyl Radical Footprinting
0 Views •
Cited by 4 •
2011
This protocol describes how to quantify the Mg(II)-dependent formation of RNA tertiary structure by two methods of hydroxyl radical footprinting.
19:44
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
0 Views •
Cited by 10 •
2012
We have synthesized a novel analogue of pancratistatin with comparable anti-cancer activity as native pancratistatin; interestingly, combinatory treatment with tamoxifen yielded a drastic enhancement in apoptotic and autophagic induction by mitochondrial targeting with minimal effect on noncancerous fibroblasts. Thus, JCTH-4 in combination with tamoxifen could provide a safe anti-cancer therapy.
09:36
Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 4. Medical Imaging Procedures
0 Views •
Cited by 8 •
2016
Here, we present an overview of the preparation and animal handling procedures required to safely perform medical imaging in an animal biosafety level 4 laboratory. Computed tomography of a mock-infected guinea pig illustrates these procedures that may be used to evaluate the disease caused by a high consequence pathogen.
01:23
Dipeptidyl Peptidase 4 Inhibitors
0 Views •
2024
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
FAQs
4-Hydroxy-tamoxifen directly influences estrogen receptor signaling through high-affinity binding. This receptor engagement can block estrogen-dependent transcription in breast tissue, limiting a transcriptional program associated with hormone responsiveness. In cancer experiments, that mechanism provides a way to examine how receptor blockade affects estrogen receptor-positive models and their responses to therapeutic treatment.
The biological response depends on the tissue context in which estrogen receptors operate. In breast tissue, receptor binding can inhibit estrogen-dependent transcription, whereas other tissues may show estrogen-like effects. This tissue specificity is important when interpreting experimental outcomes because receptor engagement does not necessarily produce identical biological consequences throughout an organism.
High-affinity binding allows 4-hydroxy-tamoxifen to engage estrogen receptors effectively and makes receptor-mediated signaling a central experimental variable. Investigators can therefore use it to study how estrogen receptor activity relates to hormone-responsive cancer biology. The resulting models help connect molecular receptor interactions with changes in tumor growth or therapeutic response.
In experimental cancer models containing tamoxifen-inducible CreERT2 recombinase, 4-hydroxy-tamoxifen serves as the activating signal. This enables researchers to control when a selected gene is activated or deleted rather than relying on an uncontrolled genetic change. Such timing is useful for linking gene function to tumor development, cancer signaling, or treatment-related outcomes.
Researchers use 4-hydroxy-tamoxifen to examine estrogen receptor signaling, hormone-responsive tumor behavior, and responses to treatment in estrogen receptor-positive breast cancer cells and tumors. Its applications can also connect drug action with mechanisms of tumor growth and treatment resistance, allowing molecular signaling and therapeutic outcomes to be studied within related experimental systems.
By blocking estrogen-dependent transcription while allowing researchers to observe cancer-model responses, 4-hydroxy-tamoxifen helps investigate why estrogen receptor-positive tumors may respond differently to therapy. When paired with inducible CreERT2 models, controlled gene activation or deletion can further test whether particular genetic changes influence tumor growth or resistance-related outcomes.